Innate Pharma/$IPHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Ticker
$IPHA
Sector
Primary listing
Employees
174
Headquarters
Website
Innate Pharma Metrics
BasicAdvanced
$116M
-
-$0.63
-
-
Price and volume
Market cap
$116M
52-week high
$2.63
52-week low
$1.17
Average daily volume
20K
Financial strength
Current ratio
1.275
Quick ratio
1.275
Long term debt to equity
-63.449
Total debt to equity
-104.004
Interest coverage (TTM)
-17.31%
Profitability
EBITDA (TTM)
-60.357
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-546.11%
Operating margin (TTM)
-599.77%
Revenue per employee (TTM)
$57,340
Management effectiveness
Return on assets (TTM)
-38.85%
Return on equity (TTM)
764.21%
Valuation
Price to revenue (TTM)
10.908
Price to book
-4.56
Price to tangible book (TTM)
-4.56
Price to free cash flow (TTM)
-1.857
Free cash flow yield (TTM)
-53.85%
Free cash flow per share (TTM)
-0.678
Growth
Revenue change (TTM)
-55.25%
Earnings per share change (TTM)
-9.89%
3-year revenue growth (CAGR)
-46.15%
10-year revenue growth (CAGR)
-9.76%
3-year earnings per share growth (CAGR)
-9.07%
10-year earnings per share growth (CAGR)
15.52%
What the Analysts think about Innate Pharma
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Innate Pharma Financial Performance
Revenues and expenses
Innate Pharma Earnings Performance
Company profitability
Innate Pharma News
AllArticlesVideos
Innate Pharma Reports Full Year 2025 Financial Results and Business Update
Business Wire·5 days ago
Innate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial Results
Business Wire·2 weeks ago
Number of Shares and Voting Rights of Innate Pharma as of February 19, 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $116M as of March 31, 2026.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of March 31, 2026.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of March 31, 2026.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) does not currently have a Beta indicator.